CHILDREN'S HEALTHCARE OF ATLANTA

Nivolumab Plus Chemotherapy Shows Superior Outcomes in Advanced Hodgkin Lymphoma

7 months ago

• A phase 3 clinical trial reveals that nivolumab combined with AVD chemotherapy significantly improves progression-free survival in advanced Hodgkin lymphoma. • Patients receiving nivolumab-AVD experienced fewer side effects and a 50% reduction in disease progression risk compared to those on brentuximab vedotin-AVD. • The study's findings suggest nivolumab-AVD could become a new standard of care, potentially reducing the need for radiation therapy, especially in younger patients. • The trial included adolescents and adults, paving the way for earlier access to checkpoint inhibitors for younger patients with advanced-stage Hodgkin lymphoma.

Phase 3 Trial of Crinecerfont Shows Promise in Treating Pediatric Congenital Adrenal Hyperplasia

a year ago

A phase 3 clinical trial has demonstrated that crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, effectively reduces elevated androstenedione levels in children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, while also allowing for a decrease in glucocorticoid doses.